The efficacy of valganciclovir for prevention of infections with cytomegalovirus and Epstein-Barr virus after kidney transplant in children.

@article{Cameron2017TheEO,
  title={The efficacy of valganciclovir for prevention of infections with cytomegalovirus and Epstein-Barr virus after kidney transplant in children.},
  author={Bernadette M Cameron and Sean E Kennedy and William D Rawlinson and Fiona E. Mackie},
  journal={Pediatric transplantation},
  year={2017},
  volume={21 1}
}
This study evaluated the efficacy of prophylactic ValGCV in preventing CMV and EBV infections in a single-center pediatric kidney transplant population (2008-2014). Therapy duration was determined according to donor/recipient serostatus. EBV monitoring was performed using monthly plasma PCR for 18 months post-transplant and for CMV, monthly for 6 months… CONTINUE READING